XKRX
207940
Market cap51bUSD
Oct 30, Last price
1,487,000.00KRW
1D
8.86%
1Q
0.13%
Jan 2017
540.48%
IPO
498.84%
Name
Samsung Biologics Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Organization (CMO) and Contract Development Organization (CDO). Its CDO services cover areas such as cell line development, optimization of upstream and downstream processes, and the formulation of analytical methods and final products. For CMO, the company offers aseptic filling, lyophilization, finishing, storage, shipping, and various associated support services. Additionally, it delivers comprehensive quality assurance, quality control, biosafety, and analytical testing. Samsung Biologics is also involved in creating and launching biosimilar drugs, alongside manufacturing mammalian cell-based antibody medications.
Key people
Diane Black
Vice President · since 2025
Pierre Catignol
Vice President · since 2021
James Choi
Vice President · since 2021
Gyu Ho Lee
Vice President · since 2024
Ho Seong Min
Vice President · since 2023
Kevin Sharp
Vice President · since 2024
Javier Camposano
Assistant Managing Director · since 2024
Seong Hwan Cho
Assistant Managing Director · since 2023
Yeong Jin Cho
Assistant Managing Director · since 2021
Seong Yil Cho
Assistant Managing Director · since 2022
Yeong Han Gu
Assistant Managing Director · since 2022
Yeon Jin Hong
Assistant Managing Director · since 2023
Do Yeong Huh
Assistant Managing Director · since 2021
Yin Chan Hwang
Assistant Managing Director · since 2024
Yong Hwan Jin
Assistant Managing Director · since 2020
Hyeong Nam Jung
Assistant Managing Director · since 2024
Ja Hun Kang
Assistant Managing Director · since 2021
Jin Han Kim
Assistant Managing Director · since 2025
Hui Jeong Kim
Assistant Managing Director · since 2021
Christina Kim
Assistant Managing Director · since 2023
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||